NIAID supports a comprehensive portfolio of research covering basic, translational, and clinical studies to better understand the national history of tuberculosis (TB) and the development of drug resistance. NIAID also provides resources and animal models to investigators worldwide to facilitate biomedical research and help move drugs, vaccines, and diagnostics closer to patients.
Through the information offered here, researchers can learn about the science being conducted at NIAID and by NIAID-funded researchers. Researchers seeking funding can access opportunities to further their own research, while NIAID and NIH grantees can find out about available resources outside of specific funding opportunities. Recent publications, active networks, and ways to connect with other researchers are also available.
Resources for Researchers
NIAID provides resources to the scientific community to advance basic through clinical research and support the development of vaccines, therapeutics, and diagnostics. Researchers do not need to be funded by NIH to access the resources. Available resources include repositories such as the BEI repository, genomics and emerging technologies, and clinical evaluation programs such as the Vaccine and Treatment Evaluation Units. Preclinical services available include the following:
- In Vitro Assessment for Antimicrobial Activity
- Preclinical Models of Infectious Diseases
- Therapeutic Development Services (including biopharmaceutical and interventional agent services)
- Vaccine Development Services (including manufacturing and testing services)
Funding Opportunities
NIAID is always accepting researcher-initiated applications. Connect with NIAID program officers about potential or related funding for tuberculosis research.
Program Officers
For contact information, search the NIH Enterprise Directory.
- Dr. Jim Boyce, Program Officer, Drug Discovery
- Dr. Katrin Eichelberg, Program Officer, Immunology and Vaccines
- Dr. Daniel Frank, Program Officer, HIV-TB Clinical Research
- Dr. Alison Kraigsley, Program Officer, Pathogen Biology
- Dr. Karen Lacourciere, Program Officer, Diagnostics, Genetics, and Epidemiology
- Dr. Barbara Laughon, Senior Scientist for Tuberculosis Drug Development Partnerships; Program Officer, Advanced Drug Development
- Dr. Susana Mendez, Program Officer, Mycobacterial Biology and Pathogenesis
- Andre McBride, Health Specialist, Preclinical Services
- Dr. Lakshmi Ramachandra, Chief, Tuberculosis and Other Mycobacterial Diseases Section, Program Officer for the Tuberculosis Research Advancement Centers (TRACs)
- Dr. Sudha Srinivasan, Program Officer, HIV-TB Clinical Research
Connect With Other Researchers
Researchers at NIAID
Much of the research conducted at NIAID on tuberculosis is done here:
- Clifton E. Barry III, Ph.D., Laboratory of Clinical Immunology and Microbiology
- Alan Sher, Ph.D., Laboratory of Parasitic Diseases
- Daniel L. Barber, Ph.D., Laboratory of Parasitic Diseases
- Katrin D. Mayer-Barber, Dr. rer. nat. (Ph.D.,) Inflammation and Innate Immunity Unit
- Robert Seder, M.D., VRC Cellular Immunology Section
Researchers Funded by NIAID
NIAID Strategic Plan for TB Research
TB is the world’s leading infectious cause of death. In its strategic plan, NIAID details five strategic priorities for building on research advances to develop the knowledge and tools to end TB globally.
Anthony S. Fauci, Addressing the Tuberculosis Epidemic: 21st Century Research for an Ancient Disease Journal of the American Medical Association DOI: 10.1001/jama.2018.12852.
National Action Plan for Combating Multidrug-Resistant Tuberculosis
- National Action Plan for Combating Multidrug-Resistant Tuberculosis, Year Three Report
- National Action Plan for Combating Multidrug-Resistant Tuberculosis, Year Two Report
- National Action Plan for Combating Multidrug-Resistant Tuberculosis, Year One Report
- National Action Plan for Combating Multidrug-Resistant Tuberculosis: Six–Month Progress Report and Future Direction
- National Action Plan for Combating Multidrug-Resistant Tuberculosis